AU2020211071A1 - New crystalline forms of a succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide - Google Patents

New crystalline forms of a succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide Download PDF

Info

Publication number
AU2020211071A1
AU2020211071A1 AU2020211071A AU2020211071A AU2020211071A1 AU 2020211071 A1 AU2020211071 A1 AU 2020211071A1 AU 2020211071 A AU2020211071 A AU 2020211071A AU 2020211071 A AU2020211071 A AU 2020211071A AU 2020211071 A1 AU2020211071 A1 AU 2020211071A1
Authority
AU
Australia
Prior art keywords
modification
ribociclib
crystalline form
salt
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020211071A
Other languages
English (en)
Inventor
Arnaud Grandeury
Nilesh Patel
Frank Schaefer
Daniel Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2020211071A1 publication Critical patent/AU2020211071A1/en
Priority to AU2023200724A priority Critical patent/AU2023200724B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020211071A 2019-01-23 2020-01-23 New crystalline forms of a succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide Abandoned AU2020211071A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023200724A AU2023200724B2 (en) 2019-01-23 2023-02-10 New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795799P 2019-01-23 2019-01-23
US62/795,799 2019-01-23
PCT/IB2020/050544 WO2020152629A1 (en) 2019-01-23 2020-01-23 New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200724A Division AU2023200724B2 (en) 2019-01-23 2023-02-10 New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Publications (1)

Publication Number Publication Date
AU2020211071A1 true AU2020211071A1 (en) 2021-07-15

Family

ID=69467591

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020211071A Abandoned AU2020211071A1 (en) 2019-01-23 2020-01-23 New crystalline forms of a succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
AU2023200724A Active AU2023200724B2 (en) 2019-01-23 2023-02-10 New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023200724A Active AU2023200724B2 (en) 2019-01-23 2023-02-10 New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Country Status (9)

Country Link
US (2) US12390468B2 (https=)
EP (1) EP3914353A1 (https=)
JP (2) JP2022517842A (https=)
KR (1) KR20210119444A (https=)
CN (1) CN113316471A (https=)
AU (2) AU2020211071A1 (https=)
CA (1) CA3124015A1 (https=)
IL (1) IL284510B2 (https=)
WO (1) WO2020152629A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240026T1 (hr) 2017-08-25 2024-03-29 Assia Chemical Industries Ltd Kruti oblik ribociklib sukcinata
US12390468B2 (en) 2019-01-23 2025-08-19 Novartis Ag Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
WO2025041004A1 (en) * 2023-08-18 2025-02-27 Alembic Pharmaceuticals Limited Polymorph of ribociclib salt
WO2025144118A1 (en) * 2023-12-27 2025-07-03 Deva Holding Novel polymorph of ribociclib dihydrochloride dihydrate and method of preparation
TW202602868A (zh) 2024-04-15 2026-01-16 瑞士商諾華公司 瑞波西利的藥物組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
EA012926B1 (ru) 2001-12-20 2010-02-26 Оси Фармасьютикалз, Инк. Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
EP1781647A2 (en) 2004-07-22 2007-05-09 Astex Therapeutics Limited Thiazole and isothiazole derivatives as protein kinase inhibitors
RU2468988C2 (ru) 2005-07-22 2012-12-10 Квалкомм Инкорпорэйтэд Устройства мэмс, имеющие поддерживающие структуры, и способы их изготовления
AU2006331765A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2818007B1 (en) 2012-02-24 2022-02-23 Nokia Technologies Oy Method and apparatus for establishing a connection with an access network based upon access network interworking information
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
US10138250B2 (en) * 2014-12-12 2018-11-27 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
US9994579B2 (en) * 2014-12-12 2018-06-12 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
EP3279201B1 (en) 2015-04-01 2019-10-23 Crystal Pharmatech Co., Ltd. Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor
HRP20240026T1 (hr) 2017-08-25 2024-03-29 Assia Chemical Industries Ltd Kruti oblik ribociklib sukcinata
WO2019111160A1 (en) * 2017-12-04 2019-06-13 Sun Pharmaceutical Industries Limited Crystalline forms of ribociclib succinate
US11111250B2 (en) * 2017-12-22 2021-09-07 Shilpa Meicare Limited Polymorphs of Ribociclib mono succinate
US11414421B2 (en) 2018-01-20 2022-08-16 Natco Pharma Ltd Process for the preparation of ribociclib succinate and its novel crystalline forms thereof
TWI675662B (zh) 2018-05-17 2019-11-01 中化合成生技股份有限公司 瑞博西尼琥珀酸鹽（Ｒｉｂｏｃｉｃｌｉｂ ｓｕｃｃｉｎａｔｅ ｓａｌｔ）晶型Ｂ、Ｃ及Ｄ與其衍生物，以及其等之製造方法與藥物組合物
US12390468B2 (en) 2019-01-23 2025-08-19 Novartis Ag Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide

Also Published As

Publication number Publication date
US20250281492A1 (en) 2025-09-11
AU2023200724B2 (en) 2025-01-23
WO2020152629A1 (en) 2020-07-30
IL284510B2 (en) 2025-10-01
IL284510A (en) 2021-08-31
JP2022517842A (ja) 2022-03-10
IL284510B1 (en) 2025-06-01
JP2024099797A (ja) 2024-07-25
AU2023200724A1 (en) 2023-03-09
EP3914353A1 (en) 2021-12-01
CN113316471A (zh) 2021-08-27
US12390468B2 (en) 2025-08-19
KR20210119444A (ko) 2021-10-05
CA3124015A1 (en) 2020-07-30
US20230042479A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
AU2023200724B2 (en) New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
AU2016203534B2 (en) Salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
JPH11509865A (ja) ５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用法
JP2018520205A (ja) レンバチニブメシル酸塩の新規結晶形及びその製造方法
CA2788774A1 (en) Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
CA2803559A1 (en) Nilotinib salts and crystalline forms thereof
TWI705060B (zh) 一種ｍｅｋ激酶抑制劑的對甲苯磺酸鹽、其結晶形式及製備方法
JP7778750B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
EP3430004B1 (en) Solid state forms of nilotinib salts
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
CN109593102B (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
JP2024530315A (ja) Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法
EP3645535B1 (en) New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it
WO2020065667A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
WO2024251230A1 (zh) 一种plk1激酶抑制剂的盐型、晶型及其制备方法和应用
CN106928218A (zh) 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
RU2857779C2 (ru) Новые кристаллические формы сукцинатной соли диметиламида 7-циклопентил-2-(5-пиперазин-1-илпиридин-2-иламино)-7h-пирроло[2,3-d]пиримидин-6-карбоновой кислоты
CN110582279B (zh) 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
CN109516976B (zh) 取代嘧啶类pi3k抑制剂甲磺酸盐的晶型及其制备方法
WO2025223554A1 (zh) 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用
HU231012B1 (hu) Lapatinib sók

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted